Vela Diagnostics has developed the manual version of the assay to enable quick adoption of the test by laboratories. Credit: Christian C Gruber Georg Steinkellner.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Vela Diagnostics has received the CE Mark for the manual version of the ViroKey SARS-CoV-2 RT-PCR Covid-19 detection test for in vitro diagnostic use.

The probe-based reverse transcription PCR test detects SARS-CoV-2 virus in patients suspected of Covid-19.

It detects SARS-CoV-2 by targeting conserved regions of the SARS-CoV-2 genome. The manual version of the assay allows quick adoption of the Covid-19 detection test by laboratories with existing Applied Biosystems 7500 Fast Dx (ABI 7500 Fast Dx) instruments.

Vela Diagnostics acting CEO and Board chairman Sam Dajani said: “The CE mark enables Vela Diagnostics to expand Covid-19 testing capacity in Europe, where there is an urgent need to identify individuals infected with SARS-CoV-2.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, the company has developed an automated version of the test. Vela Diagnostics is expected to complete CE-IVD registration by the end of the month.

The automated ViroKey SARS-CoV-2 RT-PCR Test is optimised for a workflow, consisting of the Sentosa SX101 instrument combined with the Sentosa SA201 instrument or the ABI 7500 Fast Dx.

Last week, Vela Diagnostics was contracted by the Biomedical Advanced Research and Development Authority (BARDA) in the US to support the development of its Covid-19 tests. This $225,000 contract will allow the company to carry out verification and clinical validation of the ViroKey SARS-CoV-2 RT-PCR Test.

Meanwhile, more than 2,971,831 Covid-19 cases have been reported globally with the fatality rate reaching up to 206,553.

The US, which is now the epicentre of the pandemic, has recorded over 965,910 confirmed cases and 54,876 deaths.

A few of the hardest-hit European countries like Spain, Italy and France have seen a slight drop in the number of Covid-19 cases over the past two weeks.